Pre-clinical research of YS110 in cancer
Anti-tumor activity of YS110 in pre- clinical studies, example.
Malignant mesothelioma
YS110 treatment leads to tumor regression and enhanced survival in BALB/c mice implanted with human malignant mesothelioma JMN Direct Effect against JMN Tumor
Ovarian cancer
FACS analysis of CD26 expression on ovarian carcinoma cell SK-OV-3
Effects of on tumor growth of SK-OV-3 CD26-transfectant mice in vivo
Lung cancer
CD26-positive lung carcinoma cell lines examined
Anti-CD26 mAb inhibits Lung carcinoma cell growth in vivo
Anti-CD26 mAb inhibits Lung carcinoma cell growth in vivo
Acting mechanisms of YS110 against cancer
1. ADCC/CDC (validated by our group: Clin Cancer Res. 2007;13:4191.)
ADCC (antibody-dependent cell-mediated cytotoxicity)
CDC (complement-dependent cytotoxicity)
2. Direct effects on CD26+ tumors
a. Inhibition of cell growth
b. Inhibition of invasion and metastasis
3. Effects on immune cells
a. Reduction of serum DPPIV enzyme activity
b. Immune checkpoint blockade
